J&J's Darzalex Proves Effective in Yet Another Multiple Myeloma Indication

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 22, 2020 at 11:12 PM.

  1. #1 cafead, Oct 22, 2020 at 11:12 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,962
    Likes Received:
    3
    via Denmark-based Genmab A/S announced positive topline data from the second part of the Phase III CASSIOPEIA trial. The study is evaluating daratumumab monotherapy as maintenance treatment compared to observation, in other words, no treatment, for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant (ASCT).

    The second part of the trial is being conducted by the French Intergroupe Francophone du Myelome (IFM) in collaboration with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Research & Development, a Johnson & Johnson company.

    article source
     
    Quote

Reply to Thread